Davenport E, Zhou X, Wang J, Nunna S, Oberdhan D, Fernandes A, Mekahli D. Disease burden and disease progression of young adult patients with autosomal dominant polycystic kidney disease. Poster presented at the National Kidney Foundation 2023 Spring Clinical Meeting; April 11, 2023. Austin, TX. [abstract] Am J Kidney Dis. 2023 Apr 1; 81(4, Supple 1):S102. doi: 10.1053/j.ajkd.2023.01.349
Zhou X, Davenport EK, Ouyang J, Krasa H, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across a pooled database of multiple Autosomal Dominant Polycystic Kidney Disease (ADPKD) clinical studies. Poster presented at the 2020 National Kidney Foundation Spring Clinical Meeting; March 2020. New Orleans, LA. [abstract] Am J Kidney Dis. 2020 Apr; 75(4):663.
Mader G, Purser M, Mladsi D, Sanon M, Oberdhan D, Watnick T, Seliger S. Benefit of tolvaptan on time to End-stage Renal Disease (ESRD) for patients with rapidly progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD): a disease progression model. Poster presented at the 2020 National Kidney Foundation Spring Clinical Meeting; March 2020. New Orleans, LA. [abstract] Am J Kidney Dis. 2020 Apr; 75(4):603.
Butler AM, Layton JB, Dharnidharka VR, McGrath LJ. Correspondence: In reply to 'High-dose versus standard-dose influenza vaccine in hemodialysis patients'. Am J Kidney Dis. 2020 Mar;75(3):456-7. doi: 10.1053/j.ajkd.2019.11.002
Butler AM, Layton JB, Dharnidharka VR, Sahrmann J, Seamans MJ, Weber DJ, McGrath L. Comparative effectiveness of high-dose versus standard-dose influenza vaccine among patients receiving maintenance hemodialysis. Am J Kidney Dis. 2020 Jan;75(1):72-83. doi: 10.1053/j.ajkd.2019.05.018.
Butler AM, Layton JB, Krueger WS, Kshirsager AV, McGrath LJ. Assessing residual bias in estimating influenza vaccine effectiveness: comparison of high-dose versus standard-dose vaccines. Med Care. 2019 Jan;57(1):73-8. doi: 10.1097/MLR.0000000000001018
Assimon MM, Brookhart MA, Fine JP, Heiss G, Layton JB, Flythe JE. A comparative study of carvedilol versus metoprolol initiation and 1-year mortality among individuals receiving maintenance hemodialysis. Am J Kidney Dis. 2018 Sep;72(3):337-48. doi: 10.1053/j.ajkd.2018.02.350.
Garcia-Albeniz X, Logan RW, Schrag D, Hernan MA. Evaluation of the duplication of staging CT scans for localized colon cancer in a Medicare population. Med Care. 2014 Nov;52(11):963-8. doi: 10.1097/MLR.0000000000000231
Wheeler SB, Kohler RE, Goyal RK, Lich KH, Lin CC, Moore A, Smith TW, Melvin CL, Reeder-Hayes K, Domino ME. Is medical home enrollment associated with receipt of guideline-concordant follow-up care among low-income breast cancer survivors? Med Care. 2013 Jun;51(6):494-502.
Bradbury BD, Brookhart MA, Winkelmayer WC, Critchlow CW, Kilpatrick RD, Joffe MM, Feldman HI, Acquavella JF, Wang OH, Rothman KJ. Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in non-experimental research: strengths and limitations. Am J Kidney Dis. 2009 Sep 1;54(3):554-60.
Bradbury BD, Wang O, Critchlow CW, Rothman KJ, Heagerty P, Keen M, Acquavella JF. Relative mortality and epoetin alfa dose in hemodialysis patients - Reply. Am J Kidney Dis. 2008 May 1;51(5):865-6.
Bradbury BD, Wang O, Critchlow CW, Rothman KJ, Heagerty P, Keen M, Acquavella JF. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis. 2008 Jan 1;51(1):62-70.
Schneeweiss S, Patrick AR, Sturmer T, Brookhart MA, Avorn J, Maclure M, Rothman KJ, Glynn RJ. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007 Oct 1;45(10 - Suppl 2):S131-42.
Sturmer T, Glynn RJ, Rothman KJ, Avorn J, Schneeweiss S. Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information. Med Care. 2007 Oct 1;45(10 - Suppl 2):S158-65.
Bray JW, Zarkin GA, Davis KL, Mitra D, Higgins-Biddle JC, Babor TF. The effect of screening and brief intervention for risky drinking on health care utilization in managed care organizations. Med Care. 2007 Feb 28;45(2):177-82.
Lafata JE, Pladevall-Vila M, Divine G, Ayoub M, Philbin EF. Are there race/ethnicity differences in outpatient congestive heart failure management, hospital use, and mortality among an insured population? Med Care. 2004 Jul;42(7):680-9.
Harris-Kojetin LD, Fowler FJ, Brown JA, Schnaier JA, Sweeny SF. The use of cognitive testing to develop and evaluate CAHPS 1.0 core survey items. Consumer Assessment of Health Plans Study. Med Care. 1999 Mar 1;37(3 Suppl):MS10-21.
Hays RD, Shaul JA, Williams VS, Lubalin JS, Harris-Kojetin LD, Sweeny SF, Cleary PD. Psychometric properties of the CAHPS 1.0 survey measures. Consumer Assessment of Health Plans Study. Med Care. 1999 Mar 1;37(3 Suppl):MS22-31.
Schnaier JA, Sweeny SF, Williams VS, Kosiak B, Lubalin JS, Hays RD, Harris-Kojetin LD. Special issues addressed in the CAHPS survey of Medicare managed care beneficiaries. Consumer Assessment of Health Plans Study. Med Care. 1999 Mar 1;37(3 Suppl):MS69-78.
Mauskopf J. Industry responsibility in interactive computer modeling. Med Care. 1996 Dec 1;34(12 Suppl):DS165-72.
French MT, Mauskopf JA, Teague JL, Roland EJ. Estimating the dollar value of health outcomes from drug-abuse interventions. Med Care. 1996 Sep 1;34(9):890-910.
Mauskopf JA, Austin R, Dix LP, Berzon RA. Estimating the value of a generic quality-of-life measure. Med Care. 1995 Apr 1;33(4 Suppl):AS195-202.